Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook

What happened: Conestoga Capital Advisors highlighted Repligen Corporation (NASDAQ:RGEN) as a top contributor in its Q3 2026 investor letter, noting shares surged after strong 2Q26 revenue growth. Key numbers: RGEN closed at $175.80 per share on October 27, 2026, with a market capitalization of $11.16 billion. Why it matters: The letter cites improving order trends and high-teens growth from emerging biotechnology customers as evidence of a broader recovery in bioprocessing demand, and management raised its full-year organic growth and earnings outlook. Market: +4.7% today ($184.12), +12.0% YTD, 0.3x vol — as of 16:47 UTC Verified: Q3_2026 (Oct 27) EPS $0.53 vs $0.46 est, +14.6% beat; next print ~Jan 26 Coverage: 3 outlets in 24h

Conestoga Capital Advisors highlighted Repligen Corporation (NASDAQ:RGEN) as a top contributor in its Q3 2026 investor letter, noting shares surged after strong 2Q26 revenue growth.

The letter cites improving order trends and high-teens growth from emerging biotechnology customers as evidence of a broader recovery in bioprocessing demand, and management raised its full-year organic growth and earnings outlook. Market: +4.7% today ($184.12), +12.0% YTD, 0.3x vol — as of 16:47 UTC Verified: Q3_2026 (Oct 27) EPS $0.53 vs $0.46 est, +14.6% beat; next print ~Jan 26